Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
622
Shown on this page
12
Current sort
Recently updated
Campus scope
Beth Israel Deaconess Medical Center, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Beth Israel Deaconess Medical Center, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 541–552 of 622 matching trials with a site at Beth Israel Deaconess Medical Center, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294
Site status not listed — check the official record
View directory record Official record
Conditions
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Interventions
Navitoclax, Venetoclax, Decitabine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628
Site status not listed — check the official record
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Basimglurant, Placebo
Drug · Other
Lead sponsor
Noema Pharma AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
Site status not listed — check the official record
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

NCT01298037
Site status not listed — check the official record
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
11
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational

HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

NCT01796457
Site status not listed — check the official record
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Paul Richardson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

Avo In R/R And Previously Untreated MCL

NCT04855695
Status at this site: Recruiting
View directory record Official record
Conditions
Mantle Cell Lymphoma, Refractory Lymphoma
Interventions
Acalabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Austin I Kim
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Recruiting Phase 2 Interventional

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

NCT06333262
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Obinutuzumab
Drug
Lead sponsor
Inhye Ahn
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Scarborough, Maine • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational

Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)

NCT03707743
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Dissection
Interventions
Not listed
Lead sponsor
IRCCS San Raffaele
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Stanford, California • Hartford, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

NCT06557785
Site status not listed — check the official record
View directory record Official record
Conditions
HIV Infections
Interventions
CH505M5 N197D mRNA-gp160, CH505 TF mRNA-gp160
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Active, not recruiting Phase 2 Interventional

Dostarlimab and Cobolimab in Advanced Cervical Cancer

NCT06238635
Site status not listed — check the official record
View directory record Official record
Conditions
Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
Interventions
Dostarlimab, Cobolimab
Drug
Lead sponsor
Meghan Shea
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 11:25 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib in Thrombocythemia and Polycythemia Vera

NCT04644211
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera
Interventions
Ruxolitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
4
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 11:25 AM EDT

About this Beth Israel Deaconess Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.